High hypothetical interest in physician-assisted death in multiple sclerosis

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial

Mult Scler.

Straudi S, Manfredini F, Lamberti N, Martinuzzi C, Maietti E, Basaglia N

doi: 10.1177/1352458519833901.

Aging and Cognitive FunctionsMultiple Sclerosis

Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members

JAMA Neurol.

Xia Z, Steele SU, Bakshi A, Clarkson SR, White CC, Schindler MK, Nair G, Dewey BE, Price LR, Ohayon J, Chibnik LB, Cortese IC, De Jager PL, Reich DS

doi: 10.1001/

Aging and Cognitive FunctionsMultiple Sclerosis

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Lancet Neurol.

Chan D, Binks S, Nicholas JM, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J

doi: 10.1016/S1474-4422

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

J Neurol.

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).

doi: 10.1007/s00415-019-09563-y.

Multiple Sclerosis

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study

J Neurol Neurosurg Psychiatry.

Lunde HMB, Assmus J, Myhr KM, Bø L, Grytten N

doi: 10.1136/jnnp-2016-315238.

Multiple Sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Brain.

Correale J, Gaitán MI, Ysrraelit MC, Fiol MP

doi: 10.1093/brain/aww258.

RECOMMENDED

Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Lancet Neurol.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N

doi: 10.1016/S1474-4422(19)30151-6.

Related content

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Robot-assisted gait training is not superior to intensive overground walking in multiple sclerosis with severe disability (the RAGTIME study): A randomized controlled trial

Assessment of Early Evidence of Multiple Sclerosis in a Prospective Study of Asymptomatic High-Risk Family Members

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial

Vaccination Readiness in Multiple Sclerosis

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis